No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AFMD Affimed NV
- 5.4200
- +0.1200+2.26%
Close May 3 16:00 ET
82.53MMarket Cap-712P/E (TTM)
5.5100High5.1000Low82.33KVolume5.4200Open5.3000Pre Close436.88KTurnover0.61%Turnover RatioLossP/E (Static)15.23MShares11.100052wk High1.33P/B73.17MFloat Cap2.235052wk Low--Dividend TTM13.50MShs Float242.0000Historical High--Div YieldTTM7.74%Amplitude2.2350Historical Low5.3060Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Affimed Announces Acceptance of AFM24 Clinical Abstract For EGFR-wildtype (EGFRwt) Non-Small Cell Lung Cancer (NSCLC) At The 2024 Annual Meeting Of The American Society Of Clinical Oncology
Affimed Announces Acceptance of AFM24 Clinical Abstract For EGFR-wildtype (EGFRwt) Non-Small Cell Lung Cancer (NSCLC) At The 2024 Annual Meeting Of The American Society Of Clinical Oncology
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating
Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating.
Cantor Fitzgerald Reiterates Overweight on Affimed
Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:AFMD) with a Overweight.
Affimed Price Target Raised to $5.00/Share From $1.00 by Stifel
Affimed Price Target Raised to $5.00/Share From $1.00 by Stifel
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg